Levodrop

Levodropropizine, the active ingredient in Levodrop, is a antitussive presented as an oral formulation for oral use. It treats cough by reducing the sensitivity of the cough reflex in both adults and children. GNH USA supplies Levodrop as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Levodropropizine is an antitussive that acts on the peripheral cough reflex.

Acute cough: provides symptomatic relief of sudden‑onset coughing episodes. Chronic cough: helps manage persistent cough associated with airway irritation. Cough due to upper respiratory tract infection: reduces cough reflex sensitivity and improves comfort.

Levodropropizine is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Abdominal discomfort: occasional cramps or pain. - Diarrhea: loose stools in some patients. - Headache: transient mild headache. - Dizziness: brief sensation of light‑headedness. - Dry mouth: reduced salivation.

Serious or Rare Side Effects: - Allergic reactions: rash, urticaria, or angioedema. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Hepatic dysfunction: elevated liver enzymes. - Hematologic effects: neutropenia or other blood count changes. - Anaphylaxis: rapid onset of systemic allergic response. - Respiratory depression: extremely rare, usually with concomitant CNS depressants.

When prescribing Levodropropizine, clinicians should consider several safety aspects.

Pregnancy: safety not established; use only if potential benefit justifies the risk. Breastfeeding: unknown excretion; weigh maternal benefit against possible infant exposure. Renal impairment: dose may need adjustment in severe dysfunction. Elderly: monitor for increased sensitivity to side effects such as dizziness. Drug interactions: review concomitant medications for potential additive effects. Store at ambient temperature: keep in the original container, protect from moisture and light.

Levodropropizine may interact with other medicines; careful assessment is advised.

Major Interactions (Avoid): - Other antitussives: risk of excessive cough suppression. - QT‑prolonging agents: potential additive effect on cardiac repolarisation. - Strong CYP450 inhibitors: may increase plasma concentrations of levodropropizine.

Moderate Interactions (Monitor Closely): - Antihistamines: possible enhancement of sedative effects. - Bronchodilators: monitor therapeutic response, though no direct interaction. - Alcohol: may increase dizziness or gastrointestinal discomfort.